Optimizing the diagnosis and the treatment of iron overload diseases

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 3, 2016, Pages 359-370

  Brissot, Pierre ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Ferritin; Ferroportin; Hemochromatosis; Hemojuvelin; Hepcidin; Iron chelation; Iron overload; Non transferrin bound iron; Transferrin saturation; Venesection

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; FERROPORTIN; HEPCIDIN; HFE PROTEIN; IRON; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; BIOLOGICAL MARKER; IRON CHELATING AGENT;

AGRANULOCYTOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DYSERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC SCREENING; HEMOCHROMATOSIS; HEPCIDIN DEPRIVATION SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; IRON BLOOD LEVEL; IRON CHELATION; IRON DEFICIENCY; IRON METABOLISM DISORDER; IRON OVERLOAD; KIDNEY FAILURE; LIVER BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHLEBOTOMY; RASH; REVIEW; ADVERSE EFFECTS; BLOOD; CHRONIC DISEASE; GENETIC PREDISPOSITION; GENETICS; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; PHENOTYPE; PHLEBOTOMY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84959075144     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1119043     Document Type: Review

References (66)

1. Brissot P, Loréal O. Iron metabolism and related genetic diseases: A cleared land, keeping mysteries. J Hepatol. 2015 Nov 17. pii: S0168-8278(15)00742-4. doi: 10.1016/j.jhep.2015.11.009. [Epub ahead of print] Review
2. Brissot P, Bardou-Jacquet E, Jouanolle AM, et al. Iron disorders of genetic origin: a changing world. Trends Mol Med. 2011; 17 (12): 707-713
3. Kanwar P, Kowdley KV. Diagnosis and treatment of hereditary hemochromatosis: an update. Expert Rev Gastroenterol Hepatol. 2013; 7 (6): 517-530
4. Feder JN, Gnirke A, Thomas W, et al A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13 (4): 399-408
5. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008; 358 (3): 221-230
6. Cippa PE, Krayenbuehl PA. Increased height in HFE hemochromatosis. N Engl J Med. 2013; 369 (8): 785-786
7. Hermine O, Dine G, Genty V, et al. Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. Biochimie. 2015 Sep 28. pii: S0300-9084(15)00303-X. doi: 10.1016/j.biochi.2015.09.028. [Epub ahead of print]
8. Bardou-Jacquet E, Ben AZ, Beaumont-Epinette MP, et al. Non-HFE hemochromatosis: pathophysiological and diagnostic aspects. Clin Res Hepatol Gastroenterol. 2014; 38 (2): 143-154
9. Wallace DF, Subramaniam N. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. Genet Med. 2015 Dec 3. doi: 10.1038/gim.2015.140. [Epub ahead of print]
10. Lopez A, Cacoub P, Macdougall IC, et al. Iron deficiency anaemia. Lancet. 2015 Aug 24. pii: S0140-6736(15)60865-0. doi: 10.1016/S0140-6736(15)60865-0. [Epub ahead of print] Review
11. Ribeiro S, Belo L, Reis F, et al. Iron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Rev. 2015 Aug 18. pii: S0268-960X(15)00062-4. doi: 10.1016/j.blre.2015.07.006. [Epub ahead of print]
12. Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematol Oncol Clin North Am. 2014 Aug;28(4): 683-701
13. Musallam KM, Cappellini MD, Wood JC, et al. Iron overload in non-Transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012; 26 (Suppl 1): S16-9
14. Pigeon C, Ilyin G, Courselaud B, et al A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. Biol Chem. 2001; 276 (11): 7811-7819
15. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 2001; 98 (15): 8780-8785
16. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013; 93 (4): 1721-1741
17. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46 (7): 678-684
18. Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014; 124 (16): 2569-2574
19. Hershko C, Graham G, Bates GW, et al. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978; 40 (2): 255-263
20. Brissot P, Ropert M, Le Lan C, et al. Non-Transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012; 1820 (3): 403-410
21. Kono S. Aceruloplasminemia: an update. Int Rev Neurobiol. 2013; 110: 125-151
22. De Domenico I, Ward DM, di Patti MC, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. Embo J. 2007; 26 (12): 2823-2831
23. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011; 283 (2-3): 65-87
24. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003; 102 (7): 2670-2677
25. Le Lan C, Loreal O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood. 2005; 105 (11): 4527-4531
26. Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005; 18 (2): 277-287
27. Cabantchik ZI. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front Pharmacol. 2014; 5: 45
28. Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood. 2014 Jan 9;123(2): 168-176
29. Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol. 2003; 30 (2): 131-136
30. Island ML, Jouanolle AM, Mosser A, et al A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica. 2009; 94 (5): 720-724
31. McLaren CE, Emond MJ, Subramaniam VN, et al. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload. Hepatology. 2015 Apr 23. doi: 10.1002/hep.27851. [Epub ahead of print]
32. Valenti L, Fracanzani AL, Rametta R, et al. Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol. 2012; 57 (6): 1319-1325
33. Stickel F, Buch S, Zoller H, et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet. 2014; 23 (14): 3883-3890
34. Deugnier Y, Bardou-Jacquet E, Le Lan C, et al. Hyperferritinemia not related to hemochromatosis. Gastroenterol Clin Biol. 2009; 33 (4): 323-326
35. Larroche C. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment. Joint Bone Spine. 2012; 79 (4): 356-361
36. Deugnier Y, Laine F. Dysmetabolic iron overload syndrome: a systemic disease? Presse Med. 2014; 43 (6 Pt 1): 625-627
37. Musallam KM, Taher AT. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011; 364 (15): 1476
38. de Swart L, Hendriks JC, van der Vorm LN, et al. Second International Round Robin for the Quantification of Serum Non-Transferrin-Bound Iron and Labile Plasma Iron in Patients with Iron-Overload Disorders. Haematologica. 2015 Sep 18. pii: haematol.2015.133983. [Epub ahead of print]
39. Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol. 2012; 87 (10): 977-983
40. Wood JC. Estimating tissue iron burden: current status and future prospects. Br J Haematol. 2015; 170 (1): 15-28
41. Wood JC. Impact of iron assessment by MRI. Hematology/the Education Program of the Am Soc Hematol Educ Program. 2011; (2011): 443-450
42. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005; 105 (2): 855-861
43. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363 (9406): 357-362
44. Porto G, Brissot P, Swinkels DW, et al. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet. 2015 Jul 8. doi: 10.1038/ejhg.2015.128. [Epub ahead of print]
45. Miyajima H. Aceruloplasminemia. Neuropathology. 2015; 35 (1): 83-90
46. Deugnier Y, Turlin B. Pathology of hepatic iron overload. Semin Liver Dis. 2011; 31 (3): 260-271
47. Legros L, Bardou-Jacquet E, Latournerie M, et al. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int. 2015; 35 (6): 1731-1738
48. McDonald CJ, Ostini L, Wallace DF, et al. Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders. J Hepatol. 2015 Nov;63(5):1288-1293. doi: 10.1016/j.jhep.2015.06.027. Epub 2015 Jul 4
49. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000; 343 (5): 327-331
50. HAS. French recommendations for management of HFE hemochromatosis [Internet]. Haute Autorité de Santé. 2005 [cited 2005]. Available from: http://www.has-sante.fr
51. Brissot P, Ball S, Rofail D, et al. Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment. Transfusion. 2011; 51 (6): 1331-1338
52. Pascart T, Richette P, Flipo RM. Treatment of nongout joint deposition diseases: an update. Arthritis. 2014; 2014: 375202
53. Guggenbuhl P, Brissot P, Loreal O. Haemochromatosis: The bone and the joint. Best PractRes Clin Rheumatol. 2011; 25 (5): 649-664
54. Sheth S. Iron chelation: an update. Cur Opin Hematol. 2014; 21 (3): 179-185
55. Baksi AJ, Pennell DJ. Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major. Front Pharmacol. 2014; 5: 217
56. Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-Thalassemia treated with deferasirox for at least 3 years. Gastroenterology. 2011; 141 (4): 1202-1211
57. Santos PC, Cancado RD, Pereira AC, et al. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox. Acta Haematol. 2010; 124 (4): 204-205
58. Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica. 2013; 98 (11): 1667-1676
59. Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012; 120 (18): 3829-3836
60. Aydinok Y, Kattamis A, Cappellini MD, et al. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015; 125 (25): 3868-3877
61. Elalfy MS, Adly AM, Wali Y, et al. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015 Nov;95(5):411-420. doi: 10.1111/ejh.12507. Epub 2015 Mar 27
62. Gelderman MP, Baek JH, Yalamanoglu A, et al. Reversal of hemochromatosis by apotransferrin in non-Transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice. Haematologica. 2015; 100 (5): 611-622
63. Schmidt PJ, Racie T, Westerman M, et al. Combination therapy with a Tmprss6 RNAi-Therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-Thalassemia intermedia. Am J Hematol. 2015; 90 (4): 310-313
64. Awadallah S. Protein antioxidants in thalassemia. Adv Clini Chem. 2013; 60: 85-128
65. Moayedi B, Gharagozloo M, Esmaeil N, et al A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in beta-Thalassemia major patients receiving desferrioxamine. Eur J Haematol. 2013; 90 (3): 202-209
66. Das SK, DesAulniers J, Dyck JR, et al. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload. Liver Int. 2015 Jun 16. doi: 10.1111/liv.12893. [Epub ahead of print]